目的探讨万珂治疗难治性骨髓瘤患者的疗效。方法自2005年9月至2007年3月在第四军医大学西京医院血液科单用万珂(P)及万珂联合地塞米松、阿霉素(PAD)治疗12例经至少2个 VAD 或 MP 方案化疗疾病仍处于进展状态(PD)的 MM 患者。患者年龄35～77岁,中位年龄58岁,男9例,女3例,疾病诊断及临床分期分别依照2003 Objective To investigate the therapeutic effect of Velcade on patients with refractory myeloma. METHODS: From September 2005 to March 2007, 12 patients with at least two VADs or 12 patients undergoing cardiopulmonary bypass were randomly allocated to Xike Hospital (Department of Hematology, Xijing Hospital, Fourth Military Medical University) with orphan, dexamethasone and doxorubicin (PAD) MP regimen is still progressing state of disease (PD) MM patients. Patients aged 35 to 77 years, the median age of 58 years, 9 males and 3 females, disease diagnosis and clinical staging were in accordance with 2003